



RMPDS 18TH ANNUAL SCIENTIFIC MEETING

Meeting Agenda - August 28, 2024

Time (ET)	Theme	Topic	Speaker
9:30 AM - 10:15 AM	Opening Session	Ever Changing Landscape of the Prescription Drug Crisis	Richard C. Dart, MD, PhD
10:15 AM - 10:45 AM	Prescription Drugs	FDA's Perspective to Changing Landscape	Marta Sokolowksa, PhD
10:45 AM - 11:15 AM	Falsified Medications	Falsified Medication Use in the General Population	Joshua Black, PhD
11:15 - 11:30 AM	BREAK		
11:30 AM - 12:00 PM	Mortality Data	Getting Specific: New tools for understanding overdose and the drug supply	Nabarun Dasgupta, PhD, MPH
12:00 PM - 12:30 PM	Panel	Implications of a Changing Landscape and the Path Forward - Panel Discussion	Moderator: Dr. Richard C. Dart Speakers from morning session
12:30 PM - 1:30 PM	BREAK		
1:30 PM - 2:00 PM	Psychedelics	Comparable but not Identical: The Unique Surveillance Needs of Psychedelics	Andrew Monte, MD, PhD
2:00 PM - 2:30 PM	Psychedelics	SAMHSA's emerging perspective on Psychedelics	Neeraj Gandotra, MD
2:30 PM - 3:00 PM	Psychedelics	Addressing Adverse Events	Erica Siegal, LCSW
3:00 PM - 3:15 PM	BREAK		
3:15 PM - 3:45 PM	Psychedelics	Insights from NSIHT Pilot - National Survey Investigating Hallucinogenic Trends	Kari Rockhill, PhD, MPH
3:45 PM - 4:15 PM	Panel	Forecasting the Challenges and Opportunities of the Psychedelic Drug Class - Panel Discussion	Moderator: Dr. Richard C. Dart Speakers from afternoon session
4:15 PM - 4:30 PM	Closing Remarks	Closing Remarks	Richard C. Dart, MD, PhD



RMPDS 19TH ANNUAL SCIENTIFIC MEETING

Meeting Agenda - August 27, 2025

Time (ET)	Theme	Speaker
11:00 AM - 11:45 AM	Leading a New Frontier of Psychoactive Drug Monitoring	Richard C. Dart, MD, PhD
	SECTION 1: Beyond Opioids	
11:45 AM - 12:05 PM	Polypharmacy in Older Adults	Matthew Ellis, PhD, MPE, Washington University
12:05 PM - 12:25 PM	Decreased Prevalence of Non-Medical Use Attributable to Prescription Antidepressant Use Among US Adults with Major Depressive Disorder	Hannah Burkett, PhD - RMPDS
12:25 PM - 12:45 PM	Racial Disparities in Naloxone Access: Insights from a Nationally Representative Survey	Lindsay Allen, PhD, Northwestern University
12:45 PM - 1:05 PM	CDER's Approach to Controlled Substances: Key Actions and Updates for 2024–2025	Marta Sokolowska, PhD, CDER
1:05 PM - 1:35 PM	Assessing Disease Progression Panel	Moderator: Rick Dart Panelists: Matt Ellis, Lindsay Allen, Marta Sokolowska
1:35 PM - 1:50 PM	Break	
	SECTION 2: Key Elements of Mosaic Surveillance of Psychoactive Substances	
1:50 PM - 1:55 PM	Psychedelics Opening Session	Andrew Monte, MD, PhD - RMPDS
1:55 PM - 2:20 PM	A Mature Mosaic for Psychedelic Outcomes	Andrew Monte, MD, PhD - RMPDS
2:20 PM - 2:40 PM	OPEN Longitudinal Cohort Data in Oregon and Colorado: Strengths and Limitations of Longitudinal Cohort Studies	Todd Korthuis, MD, MPH
2:40 PM - 3:40 PM	National Survey Investigating Hallucinogenic Trends (NSIHT) Findings	
	In Measurement We Trust: Psychometric Validation of Survey Items	Joshua Black, PhD, MS - RMPDS
	Frankenstein Surveys: Data Fusion to Estimate Behaviors for Rare Populations	Joshua Black, PhD, MS - RMPDS
	Beyond Prevalence: Mapping the Spectrum of Psilocybin Use with NSIHT Data	Kate Reynolds, MPH - RMPDS
	Comparison of Self-Reported Driving Under Influence of Psychedelics, Alcohol, and Cannabis Across Multiple Data Sources	Ellie Fox, MPH - RMPDS
	Types of Psychedelic Use and Associated Behaviors and Outcomes: A Latent Class Analysis	Kari Rockhill, PhD, MPH - RMPDS
3:40 PM - 3:50 PM	Psychedelic Cross-Sector Collaboration	Melissa Lavasani - Psychedelic Medicine Coalition
3:50 PM - 4:30 PM	Rising Psychedelic Use: What's Next?	Moderator: Kate Reynolds Panelists: Kari Rockhill, Andrew Monte, Joshua Black
4:30 PM - 4:40 PM	Closing Remarks	Rick Dart, MD, PhD - RMPDS